Ken Fisher Affimed N.V. Transaction History

Fisher Asset Management, LLC

  • $243 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Dec 12, 2023
BUY
$0.57 - $1.08 $510,273 - $966,834
895,217 New
895,217 $537,000
Q1 2023

Dec 12, 2023
BUY
$0.66 - $1.29 $590,843 - $1.15 Million
895,217 New
895,217 $671,000
Q4 2022

Feb 03, 2023
BUY
$1.1 - $2.45 $542,884 - $1.21 Million
493,531 Added 122.86%
895,217 $1.11 Million
Q3 2022

Nov 08, 2022
BUY
$1.96 - $3.32 $787,304 - $1.33 Million
401,686 New
401,686 $827,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email